Video Shorts
0:49
A Breeze of Optimism in a Tough Biotech Climate
a year ago
by
Feliza Mirasol
0:37
How Important Are Small Biotechs in Driving Drug Development for Rare Diseases?
a year ago
by
Feliza Mirasol
1:55
Two-Minute Mysteries: BioPharm Stories - A Mysterious Low Reading
a year ago
by
Chris Spivey(+1 more)
0:33
What Potential Do Investors See in the Rare Disease Space?
a year ago
by
Feliza Mirasol
0:17
How Enzene's US Expansion Meets Continuous Manufacturing Demand
a year ago
by
Patrick Lavery
0:20
Finding the Right CDMO Partner by Localizing Manufacturing in the US
a year ago
by
Patrick Lavery
0:22
Enzene's 20-Year Vision for Innovation and Global Impact
a year ago
by
Patrick Lavery
0:33
Why the Focus from Industry on Rare Diseases?
a year ago
by
Feliza Mirasol
0:34
Junevity's Bold Move: Using siRNA to Fight Diabetes and Obesity
a year ago
by
Christopher Cole
1:22
How tRNAs Could Revolutionize Treatment for Dravet & More
a year ago
by
Christopher Cole
0:53
AI Boosts Early Disease Detection and Diagnostic Accuracy
a year ago
by
Christopher Cole
0:23
Why Onshoring Manufacturing Is a Smart Move Today
a year ago
by
Christopher Cole
0:29
From Nice to Have to Mandatory: Pharma’s Sustainability Makeover
a year ago
by
Christopher Cole
0:25
How Tailored Drug Formulations Create Patentable Innovations
a year ago
by
Christopher Cole
1:22
Operators Are the Main Source of Contamination in Pharmaceutical Manufacturing
a year ago
by
Christopher Cole
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
4
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
5